HER2-positive Breast Cancer
Conditions
Keywords
breast cancer, her-2 positive, lapatinib, herceptin
Brief summary
This is a randomized controlled trial of HER-2 positive breast cancer patients treated with lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous anthracycline
Detailed description
This is a randomized controlled trial of HER-2 positive breast cancer patients treated with lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous anthracycline. Safety and efficacy are the primary endpoint. The positive expression of HER2 was confirmed by postoperative pathology in patients with breast adenocarcinoma (IDC). Patients who had not received any chemotherapy and targeted anti HER2 therapy. In this study, the non inferiority design method, according to the wishes of patients and signed informed consent, randomly into the group, a total of 482 patients were enrolled in the trial group: the control group =1:1. The subjects were followed up for a total of 1 years, until the disease progressed, and the toxicity was not tolerated. We want to study 84 months. The follow-up period was 5 years (the first adjuvant treatment time to the last follow-up) or the researchers decided to end the study.
Interventions
DRUGlapatinib/herceptin
Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
Sponsors
Taizhou EOC Pharma Co., Ltd.
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. the first diagnosis of invasive breast cancer, confirmed by histology or cytology, and surgical resection of the primary lesions before receiving any anti breast cancer treatment; 2. female patients, aged 18 years and less than 80 years of age; 3. surgical resection of the primary tumor pathological examination, showed HER2 positive (defined as immunohistochemistry \[IHC\] 3+ or fluorescence in situ hybridization (FISH) positive); 4. hormone receptor status is known, lymph node positive or sentinel lymph node negative but high risk factors 5. the eastern oncology cooperative group (ECOG) patients with physical status score was 0 -2; 6. baseline LVEF \>50% 7. the relevant institutional review board (IRB) or independent ethics committee (IEC) written informed consent
Exclusion criteria
1. the subjects in pregnancy or lactation; 2. pregnant women may be within the first 7 days before pregnancy test positive (urine or serum). 3. received chemotherapy, endocrine or anti HER2 anti-tumor therapy; 4. congestive heart failure, unstable angina, heart failure or myocardial infarction and other diseases; 5. other invasive tumors (including the second primary breast cancer), may affect the outcome of the evaluation and program compliance; but the treatment of patients with disease free survival at least more than 5 years can be selected; 6. with chronic liver disease in patients with liver dysfunction and / or with clinical manifestations: the serum total bilirubin \> 2.5 \* ULN; or INR = 1.5 but no bilirubin. serum ALT or AST\> \* 3 \* ULN; alkaline phosphatase \>2.5 \* ULN; ALT or AST can be gradually increased, but with gradually increasing fatigue, nausea and vomiting, fever, right upper quadrant pain or tenderness 7. hematopoietic dysfunction, defined as follows: neutrophil count (ANC) \<1.5 \* 109/L; platelet \<100 \* 109/L; hemoglobin \<9 g/dL; 8. other serious diseases, including: congestive heart failure (heart function NYHA grade II, III, IV) or occurred within 6 months of congestive heart failure, unstable angina, arrhythmia, myocardial infarction patients can't control or other severe cardiovascular disease; breathing at rest or need oxygen therapy; serious infection; uncontrolled diabetes; 9. there is a serious psychological or mental abnormalities, estimated that the participants to participate in this study is not strong; 10. known to study drug allergy; 11. the past 30 days participated in the study of other drug clinical trials. 1, failed to complete the clinical trial of at least 1 cycles according to the program, can not carry out safety and efficacy evaluation 2, a serious violation of this research program, not in accordance with the prescribed dose, method and course of medication. Patients will receive lapatinib treatment, until a predetermined end end point, or development of unacceptable toxicity, or withdrawal of consent, or illness or death, to appear before the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DFS | 3 years& 5 years | Since the first randomized to disease recurrence or death occurred due to other reasons, the recurrence of the disease include local, regional, distant, ipsilateral or contralateral breast cancer (excluding breast lobular carcinoma in situ) and non malignant tumor secondary breast (except the skin basal cell carcinoma or squamous cell carcinoma, cervical cancer in situ cancer). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 5 years & 10 years | 0S is defined as the time from randomization to death due to any cause |
Other
| Measure | Time frame | Description |
|---|---|---|
| biomarker | 5 years | A retrospective study was performed to examine the correlation between the prognosis of the two adjuvant and biomarkers, including but not limited to Ki67, PI3K, C-MYC, IGF1R, P95HER2, P53 and other biomarkers |
Countries
China
Contacts
Primary ContactSun Qiang, M.D.
Outcome results
None listed